WO1998002543A1 - Nouveaux facteurs analogues au vegf - Google Patents
Nouveaux facteurs analogues au vegf Download PDFInfo
- Publication number
- WO1998002543A1 WO1998002543A1 PCT/JP1997/002456 JP9702456W WO9802543A1 WO 1998002543 A1 WO1998002543 A1 WO 1998002543A1 JP 9702456 W JP9702456 W JP 9702456W WO 9802543 A1 WO9802543 A1 WO 9802543A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vegf
- gene
- isolated
- protein
- expected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69733204T DE69733204T3 (de) | 1996-07-15 | 1997-07-15 | Neuartige vegf-ähnliche faktoren |
JP50585698A JP3911028B2 (ja) | 1996-07-15 | 1997-07-15 | 新規なvegf様因子 |
CA2260754A CA2260754C (en) | 1996-07-15 | 1997-07-15 | Novel vegf-like factor |
AT97930804T ATE294863T1 (de) | 1996-07-15 | 1997-07-15 | Neuartige vegf-ähnliche faktoren |
EP97930804A EP0935001B2 (en) | 1996-07-15 | 1997-07-15 | Novel vegf-like factors |
US09/214,982 US6828426B1 (en) | 1996-07-15 | 1997-07-15 | VEGF-like factor |
AU34610/97A AU733322B2 (en) | 1996-07-15 | 1997-07-15 | Novel VEGF-like factor |
US10/978,107 US20050112665A1 (en) | 1996-07-15 | 2004-10-29 | Novel VEGF-like factor |
US11/397,289 US7803576B2 (en) | 1996-07-15 | 2006-04-04 | Nucleic acid sequences encoding VEGF-like factors and uses thereof |
US12/729,708 US20110293602A1 (en) | 1996-07-15 | 2010-03-23 | Vegf-like factor antibodies and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/185216 | 1996-07-15 | ||
JP18521696 | 1996-07-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09214982 A-371-Of-International | 1997-07-15 | ||
US10/978,107 Division US20050112665A1 (en) | 1996-07-15 | 2004-10-29 | Novel VEGF-like factor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998002543A1 true WO1998002543A1 (fr) | 1998-01-22 |
Family
ID=16166915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/002456 WO1998002543A1 (fr) | 1996-07-15 | 1997-07-15 | Nouveaux facteurs analogues au vegf |
Country Status (8)
Country | Link |
---|---|
US (4) | US6828426B1 (ja) |
EP (1) | EP0935001B2 (ja) |
JP (1) | JP3911028B2 (ja) |
AT (1) | ATE294863T1 (ja) |
AU (1) | AU733322B2 (ja) |
DE (1) | DE69733204T3 (ja) |
ES (1) | ES2242227T5 (ja) |
WO (1) | WO1998002543A1 (ja) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0956339A1 (en) * | 1996-08-23 | 1999-11-17 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor d (vegf-d) |
US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
JP2002532113A (ja) * | 1998-12-21 | 2002-10-02 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | 切断vegf−dの抗体及びその利用法 |
JP2003517265A (ja) * | 1997-12-24 | 2003-05-27 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 血管内皮増殖因子dを発現する発現ベクターおよび細胞系、およびメラノーマを治療する方法 |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
US6759513B2 (en) | 1996-03-12 | 2004-07-06 | Human Genome Sciences, Inc. | Death domain containing receptors |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US6818220B1 (en) | 1994-11-14 | 2004-11-16 | Licentia Ltd. | Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof |
US6965010B2 (en) | 2000-02-25 | 2005-11-15 | Licentia, Ltd. | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
US7034105B2 (en) | 1992-10-09 | 2006-04-25 | Licentia, Ltd. | FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
WO2007022287A2 (en) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Modified vegf and pdgf with improved angiogenic properties |
US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
EP1997829A1 (en) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2009082485A1 (en) | 2007-12-26 | 2009-07-02 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
US7611711B2 (en) | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
US7750125B2 (en) | 2002-06-10 | 2010-07-06 | University Of Rochester | Antibodies that bind to the C35 polypeptide |
EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7846437B2 (en) | 2004-03-05 | 2010-12-07 | Vegenics Limited | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
WO2011154308A1 (en) | 2010-06-08 | 2011-12-15 | Proyecto De Biomedicina Cima, S.L. | New compositions and cell therapy methods for the treatment of cirrhosis |
US8383788B2 (en) | 1995-09-29 | 2013-02-26 | Vegenics Pty Limited | C-Fos induced growth factor (FIGF) and DNA encoding same |
US8940695B2 (en) | 2001-01-19 | 2015-01-27 | Vegenics Pty Limited | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US9745558B2 (en) | 2013-02-18 | 2017-08-29 | Vegenics Pty Limited | VEGFR-3 ligand binding molecules and uses thereof |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1382679A3 (en) * | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
US6828426B1 (en) | 1996-07-15 | 2004-12-07 | Chugai Seiyaku Kabushiki Kaisha | VEGF-like factor |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
US6764820B2 (en) * | 1999-03-26 | 2004-07-20 | Ludwig Institute For Cancer Research | Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3) |
US20020102260A1 (en) | 2000-03-02 | 2002-08-01 | Marc Achen | Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue |
AU2006201128B2 (en) * | 2000-03-02 | 2009-05-28 | Vegenics Limited | Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D |
DK1259248T3 (da) * | 2000-03-02 | 2005-04-11 | Ludwig Inst Cancer Res | Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D |
WO2001064235A1 (en) * | 2000-03-02 | 2001-09-07 | Ludwig Institute For Cancer Research | Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d |
AU6456501A (en) * | 2000-05-03 | 2001-11-12 | Ludwig Inst Cancer Res | A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
AU2884102A (en) | 2000-12-07 | 2002-06-18 | Sangamo Biosciences Inc | Regulation of angiogenesis with zinc finger proteins |
US20040132675A1 (en) * | 2002-02-08 | 2004-07-08 | Calvin Kuo | Method for treating cancer and increasing hematocrit levels |
US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69233803D1 (de) | 1992-10-28 | 2011-03-31 | Genentech Inc | Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten |
CN1173991C (zh) | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
ATE281469T1 (de) | 1993-03-25 | 2004-11-15 | Merck & Co Inc | Inhibitor des wachstumsfaktors für gefäss- endothelzellen |
ATE280835T1 (de) | 1993-09-03 | 2004-11-15 | Chugai Pharmaceutical Co Ltd | Apoptose induzierender monoklonaler antikörper |
DE69434538T2 (de) * | 1994-03-08 | 2006-08-10 | Human Genome Sciences, Inc. | Vaskulärer endothelialer Wachstumsfaktor 2 |
US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
EP1382679A3 (en) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
EP1553182B1 (en) | 1995-09-29 | 2010-03-03 | Universita Degli Studi Di Siena | Regulated genes and uses thereof |
US6828426B1 (en) * | 1996-07-15 | 2004-12-07 | Chugai Seiyaku Kabushiki Kaisha | VEGF-like factor |
DK0956339T3 (da) * | 1996-08-23 | 2006-01-30 | Licentia Oy | Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D) |
WO1998024811A2 (en) * | 1996-12-06 | 1998-06-11 | Zymogenetics, Inc. | Vascular endothelial growth factor |
-
1997
- 1997-07-15 US US09/214,982 patent/US6828426B1/en not_active Expired - Lifetime
- 1997-07-15 AT AT97930804T patent/ATE294863T1/de not_active IP Right Cessation
- 1997-07-15 AU AU34610/97A patent/AU733322B2/en not_active Expired
- 1997-07-15 EP EP97930804A patent/EP0935001B2/en not_active Expired - Lifetime
- 1997-07-15 JP JP50585698A patent/JP3911028B2/ja not_active Expired - Lifetime
- 1997-07-15 ES ES97930804T patent/ES2242227T5/es not_active Expired - Lifetime
- 1997-07-15 WO PCT/JP1997/002456 patent/WO1998002543A1/ja active IP Right Grant
- 1997-07-15 DE DE69733204T patent/DE69733204T3/de not_active Expired - Lifetime
-
2004
- 2004-10-29 US US10/978,107 patent/US20050112665A1/en not_active Abandoned
-
2006
- 2006-04-04 US US11/397,289 patent/US7803576B2/en not_active Expired - Fee Related
-
2010
- 2010-03-23 US US12/729,708 patent/US20110293602A1/en not_active Abandoned
Non-Patent Citations (9)
Cited By (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7034105B2 (en) | 1992-10-09 | 2006-04-25 | Licentia, Ltd. | FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US6818220B1 (en) | 1994-11-14 | 2004-11-16 | Licentia Ltd. | Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof |
US7794756B1 (en) | 1995-08-01 | 2010-09-14 | Vegenics Limited | Methods of using antibodies to VEGF-C |
US7807412B2 (en) | 1995-08-01 | 2010-10-05 | Vegenies Limited | VEGF-C ΔR226ΔR227 mutants and uses thereof |
US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US8637262B2 (en) | 1995-08-01 | 2014-01-28 | Vegenics Pty Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US7709270B2 (en) | 1995-08-01 | 2010-05-04 | Vegenics Ltd. | Vascular endothelial growth factor C (VEGF-C) protein diagnostic |
US8282931B2 (en) | 1995-08-01 | 2012-10-09 | Vegenics Pty Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
US8383788B2 (en) | 1995-09-29 | 2013-02-26 | Vegenics Pty Limited | C-Fos induced growth factor (FIGF) and DNA encoding same |
US8105589B2 (en) | 1996-03-12 | 2012-01-31 | Human Genome Sciences, Inc. | Use of DR3 antibodies in the treatment of inflammatory disease |
US6759513B2 (en) | 1996-03-12 | 2004-07-06 | Human Genome Sciences, Inc. | Death domain containing receptors |
US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
US7708996B2 (en) | 1996-03-12 | 2010-05-04 | Human Genome Sciences, Inc. | DR3 antibodies |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US7871798B2 (en) | 1996-08-23 | 2011-01-18 | Vegenics Limited | Mammalian cells that express VEGF-D polypeptides |
EP1749836A3 (en) * | 1996-08-23 | 2007-08-22 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor D (VEGF-D) |
US7410639B2 (en) | 1996-08-23 | 2008-08-12 | Vegenics Limited | Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use |
EP2107109A1 (en) * | 1996-08-23 | 2009-10-07 | Vegenics Limited | Recombinant vascular endothelial cell growth factor D (VEGF-D) |
US7122654B2 (en) | 1996-08-23 | 2006-10-17 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use |
US8759286B2 (en) | 1996-08-23 | 2014-06-24 | Vegenics Pty Limited | Pharmaceutical compositions comprising a VEGF-D polypeptide |
US6689580B1 (en) | 1996-08-23 | 2004-02-10 | Ludwig Institute For Cancer Research | Growth factor |
US8227410B2 (en) | 1996-08-23 | 2012-07-24 | Vegenics Pty Limited | Methods of stimulating wound healing by administration of vascular endothelial growth factor D (VEGF-D) |
EP1283268A3 (en) * | 1996-08-23 | 2004-01-02 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor D (VEGF-D) |
US6235713B1 (en) | 1996-08-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-D (VEGF-D) polypeptides |
EP0956339A1 (en) * | 1996-08-23 | 1999-11-17 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor d (vegf-d) |
EP1749836A2 (en) * | 1996-08-23 | 2007-02-07 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor D (VEGF-D) |
US8445234B2 (en) | 1996-08-23 | 2013-05-21 | Vengenics Pty Limited | Methods of making VEGF-D polypeptides |
US7785803B2 (en) | 1996-08-23 | 2010-08-31 | Vegenics Limited | Antibody diagnostic kits and methods of use |
JP2009291198A (ja) * | 1996-08-23 | 2009-12-17 | Ludwig Inst For Cancer Research | 組換え血管内皮細胞増殖因子d(vegf−d) |
US7662932B2 (en) | 1996-08-23 | 2010-02-16 | Vegenics Limited | Vascular endothelial growth factor D (VEGF-D) polypeptides and methods of use |
EP1283268A2 (en) * | 1996-08-23 | 2003-02-12 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor D (VEGF-D) |
EP0956339A4 (en) * | 1996-08-23 | 2000-08-23 | Ludwig Inst Cancer Res | RECOMBINANT FACTOR OF VASCULAR ENDOTHELIAL CELL GROWTH (VEGF-D) |
US7928061B2 (en) | 1996-08-23 | 2011-04-19 | Vegenics Pty Limited | Methods of using VEGF-D polypeptides |
US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
JP2003517265A (ja) * | 1997-12-24 | 2003-05-27 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 血管内皮増殖因子dを発現する発現ベクターおよび細胞系、およびメラノーマを治療する方法 |
JP2002532113A (ja) * | 1998-12-21 | 2002-10-02 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | 切断vegf−dの抗体及びその利用法 |
US7179890B2 (en) | 1998-12-22 | 2007-02-20 | Janssen Pharmaceutica.N.V. | Vascular endothelial growth factor-x |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
US8278098B2 (en) | 2000-02-25 | 2012-10-02 | Vegenics Pty Limited | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
US6965010B2 (en) | 2000-02-25 | 2005-11-15 | Licentia, Ltd. | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
US7566566B2 (en) | 2000-02-25 | 2009-07-28 | Vengenics Limited | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
US7902149B2 (en) | 2000-02-25 | 2011-03-08 | Vegenics Pty Limited | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
US7309604B2 (en) | 2000-02-25 | 2007-12-18 | Licentia, Ltd. | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2236152A1 (en) | 2000-04-12 | 2010-10-06 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2216409A1 (en) | 2000-04-12 | 2010-08-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2267026A1 (en) | 2000-04-12 | 2010-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2295456A1 (en) | 2000-04-12 | 2011-03-16 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2298355A2 (en) | 2000-04-12 | 2011-03-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2357008A1 (en) | 2000-04-12 | 2011-08-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2311872A1 (en) | 2000-04-12 | 2011-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7611711B2 (en) | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
US9260526B2 (en) | 2001-01-19 | 2016-02-16 | Vegenics Pty Limited | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US8940695B2 (en) | 2001-01-19 | 2015-01-27 | Vegenics Pty Limited | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
EP2277889A2 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2990417A1 (en) | 2001-12-21 | 2016-03-02 | Human Genome Sciences, Inc. | Albumin insulin fusion protein |
EP2261250A1 (en) | 2001-12-21 | 2010-12-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1997829A1 (en) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2277888A2 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Fusion proteins of albumin and erythropoietin |
US7968688B2 (en) | 2002-06-10 | 2011-06-28 | University Of Rochester | Antibodies that bind to the C35 polypeptide |
US7750125B2 (en) | 2002-06-10 | 2010-07-06 | University Of Rochester | Antibodies that bind to the C35 polypeptide |
US7879990B2 (en) | 2002-06-10 | 2011-02-01 | University Of Rochester | Polynucleotides encoding antibodies that bind to the C35 polypeptide |
US7846437B2 (en) | 2004-03-05 | 2010-12-07 | Vegenics Limited | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
WO2007022287A2 (en) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Modified vegf and pdgf with improved angiogenic properties |
US8025886B2 (en) | 2005-08-15 | 2011-09-27 | Vegenics Pty Ltd | Modified VEGF-A with improved angiogenic properties |
US8637026B2 (en) | 2007-12-26 | 2014-01-28 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
WO2009082485A1 (en) | 2007-12-26 | 2009-07-02 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
WO2011154308A1 (en) | 2010-06-08 | 2011-12-15 | Proyecto De Biomedicina Cima, S.L. | New compositions and cell therapy methods for the treatment of cirrhosis |
US9745558B2 (en) | 2013-02-18 | 2017-08-29 | Vegenics Pty Limited | VEGFR-3 ligand binding molecules and uses thereof |
US10494617B2 (en) | 2013-02-18 | 2019-12-03 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
US11866739B2 (en) | 2013-02-18 | 2024-01-09 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0935001B2 (en) | 2011-08-10 |
ATE294863T1 (de) | 2005-05-15 |
AU3461097A (en) | 1998-02-09 |
DE69733204T2 (de) | 2006-05-11 |
DE69733204D1 (de) | 2005-06-09 |
AU733322B2 (en) | 2001-05-10 |
US6828426B1 (en) | 2004-12-07 |
US20050112665A1 (en) | 2005-05-26 |
DE69733204T3 (de) | 2012-03-08 |
ES2242227T3 (es) | 2005-11-01 |
JP3911028B2 (ja) | 2007-05-09 |
EP0935001B1 (en) | 2005-05-04 |
EP0935001B9 (en) | 2007-01-24 |
US7803576B2 (en) | 2010-09-28 |
EP0935001A4 (en) | 2000-08-23 |
US20060172343A1 (en) | 2006-08-03 |
US20110293602A1 (en) | 2011-12-01 |
ES2242227T5 (es) | 2011-12-09 |
EP0935001A1 (en) | 1999-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998002543A1 (fr) | Nouveaux facteurs analogues au vegf | |
WO1999031236A3 (en) | EXTENDED cDNAs FOR SECRETED PROTEINS | |
WO1999025825A3 (en) | EXTENDED cDNAs FOR SECRETED PROTEINS | |
EP1005540A4 (en) | IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS | |
NO973933L (no) | Vaskulær endotelvekstfaktor B | |
WO1999054461A3 (de) | Menschliche nukleinsäuresequenzen aus endometriumtumorgewebe | |
HUP9903921A2 (hu) | Tumor nekrózis faktorral rokon ligandum | |
WO1999047669A3 (de) | Menschliche nukleinsäuresequenzen aus brusttumorgewebe | |
WO1999055858A3 (de) | Menschliche nukleinsäuresequenzen aus pankreastumorgewebe | |
WO2001005825A3 (en) | Nucleic acid sequences encoding putative angiopoietin proteins | |
JP2005245268A (ja) | 血清アルブミンドメインを含む蛋白質 | |
ATE374251T1 (de) | Zusammensetzungen zur gentherapie von diabetes | |
WO2003049700A3 (en) | Growth hormone releasing hormone suplementation for treating chronically ill subjects | |
WO1997035873A3 (de) | Peptide mit antiproliferativen eigenschaften | |
Adas et al. | VEGF-A and FGF gene therapy accelerate healing of ischemic colonic anastomoses (experimental study) | |
WO2000037491A3 (en) | Dnas encoding proteins with signal sequences | |
WO2001000806A3 (en) | Dna's encoding proteins with signal peptides | |
CA2281895A1 (en) | Ikb kinases | |
WO1998011234A3 (en) | Human protein kinases | |
WO1999062561A3 (en) | Gene therapy method | |
WO2002050111A3 (en) | Isolated laminin 10 | |
WO2001087978A3 (en) | Human abc transporter and its use | |
Leibovitch et al. | Rat myogenic c-mos cDNA: cloning sequence analysis and regulation during muscle development | |
WO2000040723A3 (en) | Methods and products for delivering nucleic acids | |
CA2260754A1 (en) | Novel vegf-like factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2260754 Country of ref document: CA Ref country code: CA Ref document number: 2260754 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09214982 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997930804 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997930804 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997930804 Country of ref document: EP |